Mazdutide | Dosage Peptide 💊 Dual GLP-1/GCGR Agonist • Once Weekly Mazdutide Once-weekly dual GLP-1/glucagon receptor agonist modeled on oxyntomodulin, designed to reduce appetite and increase energy expenditure for clinically meaningful weight loss. MW ~4476 Da CAS 2259884-03-0 Dosing Once Weekly ✅ Approved in China (2025) for chronic weight management and glycemic control in adults […]

Retatrutide vs Tirzepatide | Dosage Peptide ⚖️ Incretin Comparison • Weight Loss Retatrutide vs Tirzepatide Triple agonist vs Dual agonist: comparing the next-generation incretin therapies for obesity and metabolic health. Evidence-based analysis of mechanisms, efficacy, and what to watch. 🔶 Retatrutide: GLP-1/GIP/Glucagon 🔷 Tirzepatide: GLP-1/GIP ⚡ Executive Summary Retatrutide currently shows greater average weight loss […]

Tirzepatide is a synthetic 39–amino acid peptide that acts as a dual GIP and GLP-1 receptor agonist[1]. In other words, it mimics two natural incretin hormones (GIP and GLP-1) to enhance insulin secretion and reduce appetite. It’s administered as a weekly subcutaneous injection (brand names Mounjaro® for diabetes and Zepbound™ for obesity) and has shown […]

Retatrutide (sometimes shortened in forums as “retatrutide peptide” or even “LY3437943”) is an investigational peptide that blends three hormone pathways—glucagon‑like peptide‑1 (GLP‑1), glucose‑dependent insulinotropic polypeptide (GIP) and glucagon—into one long‑acting molecule. Early trials show extraordinary weight‑loss and metabolic effects, but the drug is still in clinical development, so curious readers often ask: what is retatrutide, […]